SCHEMBL30698355

SCHEMBL30698355

COc1cc2ncc(-c3nc(Br)ccc3C#N)n2nc1C1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NRAS P01111 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ PDE4D Q08499 2/20 0.35
▸ IGF1R P08069 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ PIK3CA P42336 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.32
▸ MAPK7 Q13164 1/20 0.32
▸ AR P10275 2/20 0.32
▸ FYN P06241 5/20 0.32
▸ EGFR P00533 1/20 0.31
▸ ERBB2 P04626 1/20 0.31
▸ DYRK3 O43781 1/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ CDK5R1 Q15078 1/20 0.31
▸ DYRK2 Q92630 1/20 0.31
▸ DYRK1B Q9Y463 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31739608 0.84 NRAS (0.40) NRASFLT3PDE4DPIK3CAAR
SCHEMBL30698331 0.84 NRAS (0.40) NRASFLT3PDE4DPIK3CAAR
SCHEMBL31639299 0.79 KHK (0.34) NRASFLT3PDE4DLRRK2FYN
SCHEMBL27332552 0.79 FLT3 (0.53) NRASFLT3FYNNTRK3
SCHEMBL27328037 0.79 FLT3 (0.53) NRASFLT3FYNNTRK3
SCHEMBL24542495 0.79 FLT3 (0.42) NRASFLT3PDE4DFYNDYRK3
SCHEMBL29682761 0.79 FLT3 (0.42) NRASFLT3PDE4DFYNDYRK3
SCHEMBL27332554 0.78 FLT3 (0.46) NRASFLT3CDK2FYNCCNT1
SCHEMBL27328041 0.78 FLT3 (0.46) NRASFLT3CDK2FYNCCNT1
SCHEMBL31000231 0.76 NRAS (0.34) NRASFLT3PDE4DIGF1RCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-12-04 — — US disclosed
EP-4540248-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Children's Hospital Medical Center (US) 2025-04-23 — — EP disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 NRAS 371/4885FLT3 1/4885PDE4D 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback